 |
市场调查报告书
商品编码
1544825
眼科眼药水市场、机会、成长动力、产业趋势分析与预测，2024-2032Ophthalmic Eye Dropper Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032 |
||||||
在产品推出和技术进步激增的推动下，2024 年至 2032 年眼科滴管市场规模预计将以 6.7% 的复合年增长率成长。
该公司正在推出新的滴管型号，强调精度和用户友好性方面的尖端创新。这些进步不仅提高了剂量准确性，也提升了整体使用者体验。此外，人体工学设计、防篡改包装和复杂的跌落控制机制等功能正在被集成，使眼睛护理更加有效。例如，2023年6月，博士伦公司在美国推出了含有辅酶Q10的PreserVision AREDS 2 Formula软胶囊，拓宽了眼科解决方案的范围，并强调了该行业对推进眼部健康产品的承诺。
整个市场分为眼药水类型、模式、适应症、最终用途和地区。
根据眼药水类型，预计单剂量眼药水领域的眼科眼药水市场价值将从2024 年到2032 年以显着速度增长。越来越多的青睐。透过提供一次性应用，这些滴管可最大限度地降低污染风险并提高剂量准确性，确保无菌和用户友好的体验。
预计到2032 年，青光眼适应症领域的眼科眼药水产业将以显着的复合年增长率扩张。 。透过有效降低眼内压，这些滴管在青光眼治疗中发挥关键作用，强调了它们在维持最佳眼睛健康方面的重要性。
在人口老化不断扩大的推动下，欧洲眼科眼药水市场预计将在 2024 年至 2032 年间实现强劲成长。随着老年人口的增加，对有效的眼部护理解决方案的需求不断增加。白内障、青光眼和干眼症等疾病变得越来越普遍，眼药水提供了解决这些挑战的便捷方法。随着欧洲应对老龄化人口不断变化的需求，眼部护理解决方案（包括眼药水）的持续创新将至关重要。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 眼部疾病盛行率增加
- 眼科药物传输系统的技术进步
- 老年人口增加与疾病相伴
- 提高认识和诊断
- 产业陷阱与挑战
- 不合规和依从性差
- 相关副作用和耐受性问题
- 成长动力
- 成长潜力分析
- 2018-2032 年无防腐剂多剂量眼药水体积分析
- 监管环境
- 技术景观
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按滴管类型，2018 - 2032 年
- 主要趋势
- 单剂量眼药水
- 保存多剂量滴眼器
- 不含防腐剂的多剂量眼药水
第 6 章：市场估计与预测：按模式，2018 - 2032
- 主要趋势
- 处方药
- 非处方 (OTC) 药物
第 7 章：市场估计与预测：按指标划分，2018 年 - 2032 年
- 主要趋势
- 青光眼
- 过敏
- 结膜炎
- 干眼症
- 其他适应症
第 8 章：市场估计与预测：依最终用途，2018 年 - 2032 年
- 主要趋势
- 医院
- 眼科诊所
- 家庭护理设置
- 其他最终用户
第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- AbbVie Inc.
- Alcon Inc.
- AdvaCare Pharma
- Bausch Health Companies Inc.
- Dompe Farmaceutici S.p.A
- Novartis AG
- Pfizer Inc.
- PanOptica, Inc.
- Prestige Consumer Healthcare Inc.
- Sun Pharmaceutical Industries Ltd.
Ophthalmic Eye Dropper Market size is projected to grow at a 6.7% CAGR from 2024 to 2032, fueled by a surge in product launches and technological advancements.
Companies are unveiling new eye dropper models, emphasizing cutting-edge innovations in precision and user-friendliness. These advancements not only enhance dosing accuracy but also elevate the overall user experience. Furthermore, features like ergonomic designs, tamper-evident packaging, and sophisticated drop control mechanisms are being integrated, making eye care more effective. For instance, in June 2023, Bausch + Lomb Corporation launched its PreserVision AREDS 2 Formula soft gels with CoQ10 in the U.S., broadening the spectrum of ophthalmic solutions and underscoring the industry's commitment to advancing eye health products.
The overall market is segregated into eye dropper type, mode, indication, end-use, and region.
Based on eye dropper type, the ophthalmic eye dropper market value from the unidose eye dropper segment is forecasted to rise at a notable rate from 2024 to 2032. This is attributed to the growing preference for unidose eye droppers for their convenience and precision. By offering single-use applications, these droppers minimize contamination risks and enhance dosing accuracy, ensuring a sterile and user-friendly experience.
Ophthalmic eye dropper industry from the glaucoma indication segment is anticipated to expand at a significant CAGR through 2032. This is largely due to the critical role eye droppers play in managing glaucoma, delivering precise medication doses directly to the eye. By effectively reducing intraocular pressure, these droppers are pivotal in glaucoma management, underscoring their importance in maintaining optimal eye health.
Europe ophthalmic eye dropper market is set for robust growth between 2024 and 2032, driven by the expanding aging population. With the elderly demographic on the rise, there is an escalating demand for effective eye care solutions. Conditions like cataracts, glaucoma, and dry eye syndrome are becoming more prevalent, and eye droppers offer a convenient means to address these challenges. As Europe navigates the evolving needs of its aging population, continued innovations in eye care solutions, including eye droppers, will be paramount.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of eye disorders
- 3.2.1.2 Technological advancements in ophthalmic drug delivery systems
- 3.2.1.3 Increasing geriatric population coupled with disease
- 3.2.1.4 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Non-compliance and poor adherence
- 3.2.2.2 Associated side effects and tolerance issues
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Volume analysis of preservative-free multi-dose eye dropper, 2018-2032
- 3.5 Regulatory landscape
- 3.6 Technological landscape
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Eye Dropper Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Unidose eye dropper
- 5.3 Preserved multi-dose eye dropper
- 5.4 Preservative-free multi-dose eye dropper
Chapter 6 Market Estimates and Forecast, By Mode, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Prescription drugs
- 6.3 Over the counter (OTC) drugs
Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Glaucoma
- 7.3 Allergies
- 7.4 Conjunctivitis
- 7.5 Dry eye
- 7.6 Other indications
Chapter 8 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Ophthalmic clinics
- 8.4 Homecare settings
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 AbbVie Inc.
- 10.2 Alcon Inc.
- 10.3 AdvaCare Pharma
- 10.4 Bausch Health Companies Inc.
- 10.5 Dompe Farmaceutici S.p.A
- 10.6 Novartis AG
- 10.7 Pfizer Inc.
- 10.8 PanOptica, Inc.
- 10.9 Prestige Consumer Healthcare Inc.
- 10.10 Sun Pharmaceutical Industries Ltd.
